CONTE, Pierfranco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 37.257
EU - Europa 15.349
AS - Asia 12.713
SA - Sud America 2.171
AF - Africa 215
OC - Oceania 34
Continente sconosciuto - Info sul continente non disponibili 14
Totale 67.753
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 36.982
GB - Regno Unito 5.463
CN - Cina 4.438
SG - Singapore 3.562
IT - Italia 2.940
HK - Hong Kong 1.983
BR - Brasile 1.798
SE - Svezia 1.505
DE - Germania 1.179
UA - Ucraina 1.096
IE - Irlanda 919
TR - Turchia 715
VN - Vietnam 710
RU - Federazione Russa 632
FI - Finlandia 530
BG - Bulgaria 386
KR - Corea 342
IN - India 230
FR - Francia 206
ID - Indonesia 190
AR - Argentina 132
CA - Canada 116
MX - Messico 97
NL - Olanda 87
BD - Bangladesh 72
BE - Belgio 69
EC - Ecuador 69
IQ - Iraq 68
ZA - Sudafrica 65
PL - Polonia 64
JP - Giappone 62
ES - Italia 48
LT - Lituania 38
CO - Colombia 37
PY - Paraguay 36
AU - Australia 34
UZ - Uzbekistan 33
VE - Venezuela 32
AE - Emirati Arabi Uniti 31
MA - Marocco 31
MY - Malesia 31
PK - Pakistan 31
CL - Cile 30
AT - Austria 26
IR - Iran 26
EG - Egitto 23
AL - Albania 22
SA - Arabia Saudita 21
CZ - Repubblica Ceca 20
KE - Kenya 18
HU - Ungheria 17
NP - Nepal 17
JO - Giordania 16
PH - Filippine 16
RO - Romania 16
UY - Uruguay 16
TW - Taiwan 14
CH - Svizzera 13
DO - Repubblica Dominicana 13
GR - Grecia 13
IL - Israele 13
DZ - Algeria 12
AZ - Azerbaigian 11
BO - Bolivia 10
ET - Etiopia 10
EU - Europa 10
PE - Perù 10
TN - Tunisia 10
NG - Nigeria 9
OM - Oman 9
SK - Slovacchia (Repubblica Slovacca) 9
KZ - Kazakistan 8
PA - Panama 8
RS - Serbia 8
AM - Armenia 7
HN - Honduras 7
KG - Kirghizistan 7
LB - Libano 7
BW - Botswana 6
JM - Giamaica 6
MK - Macedonia 6
SI - Slovenia 6
TH - Thailandia 6
AO - Angola 5
BH - Bahrain 5
DK - Danimarca 5
NI - Nicaragua 5
PT - Portogallo 5
BZ - Belize 4
CI - Costa d'Avorio 4
CR - Costa Rica 4
GE - Georgia 4
MD - Moldavia 4
MN - Mongolia 4
NO - Norvegia 4
TT - Trinidad e Tobago 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AF - Afghanistan, Repubblica islamica di 3
BB - Barbados 3
BY - Bielorussia 3
Totale 67.690
Salva come PNG Salva come JPEG
Città #
Fairfield 4.172
Southend 3.802
Woodbridge 3.069
Santa Clara 2.710
Houston 2.613
Ashburn 2.591
Jacksonville 2.280
Singapore 2.185
Chandler 2.036
Hong Kong 1.968
Ann Arbor 1.736
Dearborn 1.571
Seattle 1.526
Hefei 1.524
Wilmington 1.514
Cambridge 1.375
London 926
Dublin 916
Nyköping 827
Beijing 808
Modena 630
Los Angeles 527
Chicago 470
Princeton 444
San Diego 423
Sofia 380
Eugene 379
Izmir 363
The Dalles 349
Seoul 324
New York 309
Ho Chi Minh City 281
Milan 228
Council Bluffs 204
Des Moines 201
Moscow 194
Salt Lake City 190
Buffalo 189
Shanghai 187
São Paulo 169
Columbus 155
Helsinki 152
Falls Church 142
Jakarta 140
Rome 138
Munich 136
Dallas 134
Hanoi 130
Boardman 117
Elk Grove Village 111
Tampa 97
Norwalk 92
Bologna 86
Guangzhou 72
Frankfurt am Main 70
Brussels 65
Lancaster 63
Redwood City 57
Phoenix 56
Dong Ket 54
Fremont 51
Turin 51
Naples 50
Bremen 49
Kunming 48
Rio de Janeiro 48
Warsaw 48
Nanjing 47
Redondo Beach 47
Belo Horizonte 45
Sterling 45
Tokyo 45
Atlanta 44
Denver 42
Brooklyn 38
Kilburn 38
Brasília 36
Florence 36
Porto Alegre 36
Stockholm 36
Bari 35
Mexico City 34
San Mateo 34
Chennai 33
Curitiba 33
Hounslow 33
Turku 33
Orem 32
Verona 31
Montreal 30
Zhengzhou 30
Tashkent 29
Kent 28
Nuremberg 28
Wuhan 28
Dulles 27
Da Nang 26
Padova 26
Genoa 25
Johannesburg 25
Totale 50.137
Salva come PNG Salva come JPEG
Nome #
VALORE PROGNOSTICO E PREDITTIVO DI p53 NEL CARCINOMA MAMMARIO TRATTATO CON CHEMIOTERAPIA NEOADIUVANTE 1.011
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVO 432
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 390
Rigenerand srl - Spin off Università di Modena e Reggio Emilia 380
MSC-delivered soluble TRAIl and paclitaxel as novel combinatory treatment for pancreatic adenocarcinoma 379
GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion. 369
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 367
Cytogenetic abnormalities and clinical features in a patient cohort affected by three or more synchronous or metachronous primitive malignancies. 359
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 350
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer 347
Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy 339
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. 335
Neoadjuvant treatment with Single – Agent Cetuximab Followed by 5-Fu, Cetuximab, and Pelvic Radiotherapy: A Phase II Study in Locally Advanced Rectal Cancer. 332
A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study) 330
A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing 328
MSC and Tumors: Homing, Differentiation and Secretion Influence The Therapeutic Potentials 326
Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer 325
SOLUBLE TRAIL-ARMED HUMAN AD-MSC AS NOVEL CELL THERAPY APPROACH FOR PANCREATIC DUCTAL ADENOCARCINOMA 325
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB) 325
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. 320
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 319
Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma 315
Le Cellule Staminali Mesenchimali: Aspetti Biologici ed Approcci Terapeutici 314
MODULAZIONE DELL’ESPRESSIONE DI BIOMARCATORI E PROGNOSI IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO OPERABILE SOTTOPOSTE A CHEMIOTERAPIA PREOPERATORIA 310
Mesenchymal progenitors aging highlights a mir-196 switch targeting HOXB7 as master regulator of proliferation and osteogenesis 307
Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria 303
Isolation, characterization, and transduction of endometrial decidual tissue multipotent mesenchymal stromal/stem cells from menstrual blood 300
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 299
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial . 294
Phase I study of intraperitoneal MHC unrestricted adoptive cell therapy with TALL-104 cells in patients with peritoneal carcinosis 293
Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM 293
METHOD FOR PRODUCTION OF ANTI-TUMOR TRAIL PROTEIN 288
Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas 288
FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer 285
CHER LOB Trial: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer--Safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data 285
Achievements and unmet needs in the management of advanced ovarian cancer 282
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis 279
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 277
Restoration and reversible expansion of the osteoblastic hematopoietic stem cell niche after marrow radioablation 273
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. 273
Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer.. 271
Laparoscopic approach of gastric gastrointestinal stromal tumors (GISTs): Is it still a courageous choice? Report of two cases 266
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 263
3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer 263
Immune characterization of breast cancer metastases: prognostic implications. 263
Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial 262
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). 260
Prognostic and Predictive Value of Baseline and Posttreatment Molecular Marker Expression in Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy 259
Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer 254
Preoperative chemotherapy plus lapatinib or trastuzumab or both in Her2 positive operable breast cancer. EGF109085-LAP106988/CHERLOB Trial. 254
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer 253
Donor Cell-Derived Osteopoiesis Originates from a Self-Renewing Stem Cell with a Limited Regenerative Contribution after Transplantation 253
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 252
A phase I-II study of oral doxifluridine plus radiotherapy in radiosensitive tumors of the pelvic region. 250
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 250
Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer 249
A dose-finding study of ifosfamide by three-day continuous infusion in pretreated, advanced breast cancer patients. 246
Significance of lymph node sampling in epithelial carcinoma of the ovary. 246
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study 245
9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER. 245
Incidence and clinical impact of sterilized disease and minimal residual disease after preoperative radiochemotherapy for rectal cancer 238
Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of After-6 protocol 1 235
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy 232
Prognostic value of "Dworak" tumor regression grade (TRG) after pre-operative chemo-radiotherapy in rectal cancer (RC) 231
Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy. 231
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 230
Magnetic resonance imaging and ultrasonography in predicting pathologic extent after preoperative chemotherapy in stage II-III breast cancer 227
Rare breast cancer subtypes: Histological, molecular, and clinical peculiarities 226
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y) 226
Gastrointestinal stromal tumor and other primary metachronous and synchronous neoplasms as a suspicious criterion for syndromic setting 225
Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer 225
PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY) 224
Timing for starting second-line therapy in recurrent ovarian cancer 224
Paclitaxel and vinorelbine in anthracycline pretreated breast cancer: a phase II study. 223
Bevacizumab and osteonecrosis of the jaw: Incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer 223
Cardiotoxicity of Epirubicin/Paclitaxel Containing Regimens: Role of Cardiac Risk Factors 221
Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. 221
Primary adrenal gland carcinosarcoma associated with metastatic rectal cancer: a hitherto unreported collision tumor 221
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy 219
Device for cell culture 217
Primary Systemic Therapy in operable breast cancer: clinical data and biological fall-out 216
PROLIFERATION AND APOPTOSIS BEFORE AND AFTER PRIMARY SYSTEMIC THERAPY FOR OPERABLE BREAST CANCER 216
Biomarkers predicting clinical benefit: fact or fiction? 214
Trans-CHER-Lob: A Biomarker Analysis of the Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Trastuzumab, Lapatinib or Combined Trastuzumab and Lapatinib in HER2 Positive Operable Breast Cancer. 208
Analysis of Bevacizumab (Bev) Therapy, Bisphosphonate Use and Osteonecrosis of the Jaw (ONJ) in >1900 Patients Treated in Two Randomized, Controlled Trials 207
A phase II study with danazol in metastatic breast cancer. 206
Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer: results of the randomized phase II CHER-LOB study 205
Intraperitoneal versus Intravenous Cisplatin in Combination with Intravenous Cyclophosphamide and Epidoxorubicin in Optimally Cytoreduced Advanced Epithelial Ovarian Cancer: A randomized trial of the Gruppo Oncologico Nord Ovest. 204
Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. 204
In response to Body letter to the editor regarding "Safety of intravenous and oral Bisphosphonates and compliance with dosing regimens" 203
Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts 203
Accelerated epirubicin-ifosfamide-dacarbazine regimen in patients with adult soft tissue sarcomas. 202
CHER-LOB: PREOPERATIVE CHEMOTHERAPY PLUS TRASTUZUMAB, LAPATINIB OR BOTH IN HER2-POSITIVE OPERABLE BREAST CANCER – PRELIMINARY SAFETY REPORT WITH FOCUS ON CARDIAC TOLERABILITY 202
Triple-negative breast cancer: current management and future options. 202
Chemotherapy versus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second look. 201
Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: A case report 201
High – dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study 201
Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment. 200
Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: A pilot study in patients with metastatic colorectal cancer 198
The sequential use of endocrine treatment for advanced breast cancer: where are we? 197
Totale 27.259
Salva come PNG Salva come JPEG
Categoria #
all - tutte 274.831
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 274.831
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.704 0 0 0 0 0 397 617 874 264 846 396 310
2021/20226.219 88 931 783 382 147 259 445 325 648 469 962 780
2022/20236.351 741 573 316 510 659 906 77 541 1.521 83 257 167
2023/20243.774 182 248 204 229 705 349 393 705 125 114 163 357
2024/202511.504 362 159 183 872 2.139 1.812 493 761 1.480 780 1.022 1.441
2025/202611.538 1.329 1.003 2.221 3.016 3.369 600 0 0 0 0 0 0
Totale 68.115